The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Mineralys Therapeutics, Inc. | COM | 603170101 | 79,073,379 | 9,194,579 | SH | SOLE | 9,194,579 | 0 | 0 | |||
| HilleVax, Inc. | COM | 43157M102 | 21,009,033 | 1,308,974 | SH | SOLE | 1,308,974 | 0 | 0 | |||
| Phathom Pharmaceuticals, Inc. | COM | 71722W107 | 6,591,513 | 721,962 | SH | SOLE | 721,962 | 0 | 0 | |||